TrialAnnals of oncology : official journal of the European Society for Medical Oncology2022

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.

S Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.